Amylyx Pharmaceuticals Files 8-K for Material Agreement

TL;DR

AMYX signed a big deal, details TBD.

AI Summary

On June 21, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for Amylyx Pharmaceuticals, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• Amylyx Pharmaceuticals, Inc. (company) — Registrant
• June 21, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AMLX Nasdaq Glo
• $35.1 million — reement) (the "Transferred Assets") for $35.1 million plus the aggregate amount of Determined

Filing Documents

• amlx-20240621.htm (8-K) — 50KB
• amlx-ex10_1.htm (EX-10.1) — 656KB
• 0000950170-24-076339.txt ( ) — 910KB
• amlx-20240621.xsd (EX-101.SCH) — 26KB
• amlx-20240621_htm.xml (XML) — 4KB

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement On June 21, 2024, Amylyx Pharmaceuticals, Inc., a Delaware corporation (the "Company"), entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Eiger BioPharmaceuticals, Inc., a Delaware corporation (the "Seller"), pursuant to which, subject to the terms and conditions set forth in the Asset Purchase Agreement, the Company agreed to acquire substantially all of the Seller's rights, title, and interests in, to and under those assets and interests used by the Seller in the development, manufacture, and commercialization of Avexitide (as such term is defined in the Asset Purchase Agreement) (the "Transferred Assets") for $35.1 million plus the aggregate amount of Determined Cure Costs and Assumed Liabilities (as such terms are defined in the Asset Purchase Agreement) (the "Transaction"). The Asset Purchase Agreement contains customary representations and warranties of the parties and is subject to a number of closing conditions, including, among others, (i) the accuracy of representations and warranties of the parties; (ii) the entry of an order approving the Asset Purchase Agreement and the transactions therein by the Bankruptcy Court (as defined below); (iii) compliance in all material respects with the obligations of the parties set forth in the Asset Purchase Agreement; and (iv) the receipt by the Seller of certain third-party consents. The Seller and its direct subsidiaries filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Northern District of Texas (the "Bankruptcy Court") under the caption In re Eiger BioPharmaceuticals, Inc., et al , Case No. 24-80040, which commenced on April 1, 2024. The foregoing description of the Asset Purchase Agreement remains subject to approval by the Bankruptcy Court, is not complete, and is qualified in its entirety by reference to the Asset

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AMYLYX PHARMACEUTICALS, INC. Date: June 21, 2024 By: /s/ James M. Frates James M. Frates Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR